top of page

Time to review past achievements and planning next steps at BioRN Members’ Assembly


Gitte Neubauer (BioRN Executive Board Chair) opening the Members' Assembly. Source: BioRN.

Heidelberg, 18 December. BioRN Members’ Assembly took place yesterday at the Technology Park Heidelberg. More than 50 member representatives gathered to throw a look back to the almost closed 2019 and take important decisions for the upcoming year.

BioRN Executive Board and Managing Director jointly guided the members through latest results of the implemented new strategy with a specific attention to BioRN translational activities, namely the innovation scouting project HAEP, HDDiscovery and HDIncubator (more information).


Moreover, Wolfgang Niopek received the BioRN honorary membership for his long commitment and remarkable contribution within BioRN Network. He has been part of the executive board from 2008 to 2017, and shortly before his retirement has been a member of the strategic board.


Finally, the executive board has been re-elected, including two new members: Claus Kremoser (Phenex Pharmaceutical) and Stefan Simianer (AbbVie), who substitute Stefan Herr (EMBL Venture) and Axel Wiest (Merck), leaving the board after two years of excellent work.

Similarly, Ulrich Betz (Merck), Andreas Kempff (IHK Rhine-Neckar) and Rainer Wessel (DKFZ) are the new addition to the strategic board that has been confirmed for the upcoming two years.


BioRN Team, boards and members did not miss the occasion to celebrate together the end of the year and to toast to a successful and productive 2020.



BioRN is the science and industry cluster of the Rhine-Main-Neckar region around Heidelberg, one of Germany’s strongest biotech hubs. It is a non-profit network fostering health innovations and serving its members by creating a rich translational ecosystem as well as promoting, representing and connecting the regional innovation stakeholders.

Our vision is to develop the region into a world-leading life science cluster attracting international investments and top global talent.

BioRN has more than 100 institutional members, including the top academic and research institutions, 7 global pharmaceutical companies, a large range of small and medium-sized enterprises bolstering the life science ecosystem as well as local government organizations and interest groups. www.biorn.org


bottom of page